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ABSTRACT
Background
The BC Cancer agency Gastro-intestinal Tumor 
Group supports one standard of care (s o c ) chemo-
therapy regimen for metastatic esophagogastric 
adenocarcinoma—specifically, weekly cisplatin and 
5-fluorouracil (5f u) infusion. All other regimens re-
quire Compassionate Access Program (c a p ) approval 
for public funding.
Objectives
We examined response, toxicity, and survival after 
first-line c a p  chemotherapy (c a p 1), or s o c  and second-
line c a p  chemotherapy (c a p 2).
Patients and Methods
We searched c a p  records for december 1999 to april 
2006, abstracted charts, constructed a database, and 
undertook survival analyses. Treatment response, se-
rious toxicities, and hospitalizations were recorded.
Results
We identified 32 esophageal (10 gastroesophageal 
junction) and 53 gastric cancer (62%) patients, 55 
of whom were stage M1 at diagnosis. Prior therapy 
consisted of chemoradiotherapy (n = 14), adjuvant 
chemotherapy (n = 3), and radical surgery (n = 34). 
Of these 85 patients, 50 received c a p 1, and 35 
received s o c , then c a p 2. docetaxel and irinotecan 
regimens accounted for 34% and 36%, 5% and 
55%, 16% and 32% respectively of first-, second-, 
and third-line c a p  requests. Partial responses were 
documented with s o c  (11/35, 31%) and c a p 1 (6/50, 
12%). Grade 3+ toxicity rates were 19/50 (38%) and 
6/35 (17%) with c a p 1 and s o c  chemotherapy. With 
c a p  chemotherapy, 20 hospitalizations occurred, and 
with s o c  chemotherapy, 2 hospitalizations. For all 
patients, median follow-up and survival times were 
8.9 months and 9.7 months respectively.
Limitations
This is a retrospective analysis of patients deemed 
suitable to receive non-s o c  chemotherapy regimens 
or unsuitable to receive s o c  chemotherapy.
Conclusions
Toxicities in c a p  chemotherapy regimens were sub-
stantial. Survival times were consistent with results 
of international phase ii and iii trials in esophago-
gastric cancer.
KEY WORDS
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1.  INTRODUCTION
Implementation of new chemotherapy protocols at 
the BC Cancer Agency (b c c a ) is subject to approval 
by the Priorities and Evaluation Committee (p e c) and 
the Systemic Therapy Program (s t p). Reports of the 
effectiveness of new therapies in journals and con-
ference proceedings lead to their evaluation by b c c a  
tumour groups, whose members advance appropriate 
protocols to p e c for approval and to s t p for funding. 
Normally, phase iii clinical trial data with adequate 
follow-up—or meta-analyses—are required to sup-
port major new programs. For less common malig-
nancies, only phase ii data may be available. In the 
period between the results of phase ii and iii trials, or 
before p e c and s t p approval, utilization of evolving 
therapies may be requested through the Compassion-
ate Access Program (c a p ).
Esophagogastric adenocarcinoma treatment has 
progressed in the past decade to include adjuvant 
and primary chemoradiotherapy for esophageal 
cancer 1,2 and postoperative chemoradiotherapy for 
gastroesophageal junction and gastric adenocarcin-
omas 3. These results led to the introduction at b c c a  
of g i e f u p r t  [cisplatin, infusional 5-fluorouracil (5f u), 
radiation therapy] and g i g a i r t  (5-fluorouracil, folinic 10
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acid, and radiation therapy) regimens for esophageal 
and gastric cancers respectively 4,5 (Table i). For in-
curable metastatic esophagogastric adenocarcinoma, 
the b c c a  Gastro-intestinal Tumour Group supports 
one standard-of-care (s o c ) chemotherapy regimen 
incorporating weekly infusional 5f u and cisplatin 
(g i f u c  6,7). All other regimens require c a p  approval 
for public funding. The present report describes the 
b c c a  experience with various regimens for metastatic 
esophagogastric adenocarcinoma in the second line 
after s o c  chemotherapy (c a p 2), or in the first line 
instead of s o c  (c a p 1). The principal objective of this 
type of practice review is to assist future treatment 
decision-making by assessing the total provincial 
patient experience, which would otherwise be 
unknown to individual physicians.
2.  PATIENTS AND METHODS
This retrospective review was approved by the 
research Ethics Board of the b c c a  and University 
of British Columbia. It includes patients with sur-
gically incurable esophagogastric adenocarcinoma 
who received a chemotherapy regimen through the 
c a p  either as initial therapy (c a p 1) or in the second 
line (c a p 2) after the current s o c  regimen of cispla-
tin and infusional 5f u  6,7. Patients were identified 
from the database of the b c c a  c a p , which approves 
funding and collects data prospectively on these 
patients. The b c c a  clinical records and local hospi-
tal records were retrieved, and the relevant clinical 
and pathology information was abstracted into a 
separate database for analysis. The time period was 
77 months from december 1, 1999, through april 
30, 2006.
Database fields included date of birth and sex; 
disease stage at diagnosis, primary site, and date of 
diagnosis; prior surgical, radiotherapy, and adjuvant 
chemotherapy status; initial and subsequent chemo-
therapy regimen or regimens; start and finish dates 
for chemotherapy; worst toxicity grade and type 
recorded; number of hospital days attributable to 
chemotherapy complications; response category if 
documented; date of last follow-up and patient status 
at that time. Overall survival was defined as time 
from diagnosis until death from any cause, calculated 
using the Kaplan–Meier method 8. data were analyzed 
using the Statistical Software Package for the Social 
Sciences (SPSS, version 10.1 for Windows: SPSS, 
Chicago, IL, U.S.A.).
3.  RESULTS
A total of 85 patients [61 men (72%), 24 women; 68 
Caucasian, 15 asian, 2 Fijian; median age: 56.2 years 
(range: 28.7–81.8 years)] received c a p  chemotherapy 
regimens for esophagogastric adenocarcinoma 
(Table ii). Disease stage was M1 in 55 patients at 
diagnosis. The primary tumours were gastric (n = 53) 
and esophageal (n = 32), with 10 gastroesophageal 
junction tumours in the latter group. Prior therapies 
included radical surgery (n = 34), chemoradiotherapy 
(n = 14), and adjuvant chemotherapy (n = 3). Of the 
patients who received c a p 1 chemotherapy (n = 50), 
25, 9, and 2 received second-, third-, and fourth-line 
chemotherapy respectively. reasons for using c a p 1 
included failure of prior adjuvant therapy [n = 13: 
f o l f i r i (5f u, irinotecan, leucovorin), 5; d c f  (doc-
etaxel, cisplatin, 5f u), 3; other regimens, 5], physi-
cian preference [n = 22: d c f , 8; f o l f i r i, 8; g i e f u p  
(cisplatin, infusional 5f u, with or without radiation 
therapy), 6, of whom 2 received concomitant radia-
tion therapy], and patients unsuitable for, or declin-
ing, cisplatin or infusional 5f u (n = 15). There was 
a trend toward younger age patients receiving c a p 1 
chemotherapy (median age: 55.3 years vs. 60.3 
years). In 35 patients, s o c  was followed by c a p 2 
chemotherapy. docetaxel and irinotecan regimens 
accounted for 34% and 36%, 5% and 55%, and 16% 
and 32% of first-, second-, and third-line c a p  chemo-
therapy regimens respectively.
The proportions of patients experiencing grade 3 
or 4 toxicity with s o c  chemotherapy and with c a p 1 
chemotherapy were 5/35 (17%) and 19/50 (39%) re-
spectively. There were 20 hospitalizations attributable 
to c a p 1 or c a p 2, and 2 attributable to s o c  chemother-
apy. Toxicity caused 1 death (f o l f i r i regimen). Partial 
responses were seen with s o c  (11/35) and c a p 1 (6/50) 
chemotherapy. Second-line chemotherapy produced 4 
responses: 2 after failing s o c , and 2 after failing c a p 1. 
Median follow-up was 8.9 months.
Median survival time for all patients was 
9.7 months [95% confidence interval (c i ): 6.2 to 
13.1 months]. Figures 1 and 2 present survival an-
alyses according to primary site and c a p 1 or c a p 2 
chemotherapy. Median survival for patients who had 
received no prior chemotherapy (n = 68) was 11.6 
months (95% c i : 8.4 to 14.9 months); for those who 
had received prior chemotherapy, it was 5.2 months 
(95% c i : 2.4 to 7.9 months). Median survival for pa-
tients over 50 years of age at diagnosis (11.6 months) 
t a b l e  i  BC Cancer agency esophagogastric cancer protocols
Protocol 5-Fluorouracil Cisplatin Folinic acid Cycle
g i f u c 1000 mg/m2 infusion, daily for 2 days 25 mg/m2 once, day 1 — 7 days
g i e f u p r t 1000 mg/m2 infusion, daily for 4 days 25 mg/m2 for 3 days — 28 days
g i g a i r t 425 mg/m2 bolus, daily for 5 days 20 mg/m2 daily for 5 days 28 days11
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advanced gastric cancer, d c f  yields a longer median 
survival (9.2 months vs. 8.6 months) and a better 
2-year survival rate (18% vs. 9%), which led to its 
approval by the U.S. Food and drug administration 
for gastric and gastroesophageal junction cancers 9. 
Grades 3 and 4 non-hematologic and neutropenic 
toxicity rates were 81% and 84% respectively with 
d c f  9. The editorial that accompanied publication 
(“Does the punishment fit the crime?”) reflects the 
balance required between survival gains and toxicities 
experienced 17. Overall survival after e c f  (epirubicin, 
cisplatin, 5f u) chemotherapy was longer than that 
with f a m t x  (doxorubicin, 5f u, leucovorin, methotrex-
ate: 8.9 months vs. 5.7 months) at the cost of more 
nausea, vomiting, and alopecia, and fewer episodes of 
neutropenia and infection 10. Survival after f o l f i r i was 
equivalent to that after c f , but more grade 3+ diarrhea 
occurred with f o l f i r i (22% vs. 7%) and more grade 3 
neutropenia occurred with c f  (52% vs. 25%) 12. There 
is no standard second-line chemotherapy regimen for 
gastric cancer after failure of either adjuvant or first-
line chemotherapy 16.
In metastatic esophageal cancer, chemotherapy 
is usually limited to patients with a good perform-
ance status (Eastern Cooperative Oncology Group 
≤ 2), preferably in a clinical trial. A regimen of 
cisplatin–5f u has been used most frequently. Other 
regimens include e c f , irinotecan–cisplatin, paclitax-
el–c f , paclitaxel–carboplatin, gemcitabine–cisplatin, 
f o l f i r i, and capecitabine (in place of 5f u)–oxaliplatin. 
Two regimens are the recommended maximum, 
because of a lack of a proven survival benefit. Regi-
men choice depends in part on prior chemotherapy 
received, organ function status (especially renal 
status), and issues of venous access 15.
f i g u r e  1  Kaplan–Meier analysis of overall survival by primary 
tumour site.
t a b l e  ii  Patient characteristics by Compassionate access Program 
(c a p ) usage
Pts Men Median Prior M1
(n) [n (%)] age chemotherapy at diagnosis
(years) [n (%)] [n (%)]
c a p 1 50 38 (76) 55.3 16 (32) 29 (58)
s o c /c a p 2 35 23 (66) 60.4 1 (3) 27 (77)
Pts = patients; c a p 1 = c a p  used in the first line; s o c  = standard of 
care; c a p 2 = c a p  used in the second line.
was longer than that for patients under 50 years of 
age (6.6 months).
4.  DISCUSSION
New chemotherapy regimens have been extensively 
studied in esophageal and gastric adenocarcino-
mas 9–14. Improvements in survival have been dem-
onstrated in phase iii trials in gastric cancer, but only 
phase ii trials have been undertaken in metastatic 
esophageal cancer, mainly because of small numbers 
of suitable patients. Patients with gastroesophageal 
junction cancer are sometimes included in gastric 
cancer trials on the assumption that those diseases 
are biologically similar. With the increasing use of 
adjuvant regimens in esophagogastric cancer, more 
patients with advanced disease have been previously 
exposed to at least a fluoropyrimidine.
debate continues in North america about the rela-
tive merits of newer regimens in metastatic esophago-
gastric cancer, especially when survival differences 
are small and toxicity rates are equal or greater 15,16. 
For example, as compared with c f  (cisplatin, 5f u) in 
f i g u r e  2  Kaplan–Meier analysis of overall survival (O s ), comparing 
C a p1 with standard of care (s O C ) and C a p2 chemotherapy. Median 
O s  was 7.5 months (C a p1) and 13.6 months (s O C  and C a p2).12
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Integration of new or nonstandard chemotherapy 
regimens into clinical practice occurs in response 
to evolving clinical trial results, adequate levels of 
evidence, and availability of drugs with differing 
modes of action and toxicity profiles. Typically, the 
institutional process for approval of a new regimen 
or indication takes several months, during which 
time c a p  access may be available. Physicians may 
apply to use a novel regimen in the first line if there 
are any clinical contraindications to the current b c c a  
s o c . However, many regimens shown to be active in 
phase ii trials are not advanced to full systemic therapy 
approval because of infrequent usage.
Our experience with the use of nonstandard regi-
mens in the first line (c a p 1) in metastatic esophago-
gastric cancer is reported in conjunction with that in 
patients on s o c  who later receive c a p  regimens (c a p 2). 
Both groups of patients are inevitably “selected” in 
terms of reasons for c a p 1 use—for example, better 
performance status in some cases (d c f  regimen), 
diminished organ function (for example, favouring 
irinotecan regimens over cisplatin in the presence of 
renal dysfunction), or failure of prior adjuvant therapy 
or radical chemoradiotherapy. Furthermore, patients 
were all deemed sufficiently fit to receive both c a p 1 
and c a p 2 regimens. Notably, only 50% of c a p 1 
patients received secondary therapies; by definition, 
all c a p 2 patients had received s o c  therapy first. Hence 
there is potential bias in both directions.
response assessments in retrospective analyses 
such as the present one are problematic, because 
they are not protocol-mandated and are subjective in 
terms of symptom and palliative benefit. Unlike the 
20% seen in the present series, few or no patients 
had received prior chemotherapy in most published 
trials (Table iii). The hard endpoint is survival, and 
the observed survival time (median: 9.7 months) and 
proportion (10.4% at 2 years) in the present series are 
consistent with contemporary clinical trials. Median 
survival after g i f u c  chemotherapy in 205 patients 
across British Columbia between 2001 and 2006, 
25% of whom received second-line or subsequent 
chemotherapy, was 11.2 months 18. Conservatively 
interpreted, this survival appears to be at least as good 
as the median survival for all patients in the present 
series (9.7 months) and for those who received c a p 1 
chemotherapy (7.5 months).
an examination of toxicity rates between s o c  
and c a p 1 patients is subject to less potential bias. 
despite patients being selected as suitable for c a p  
therapies, severe toxicity and hospitalization rates 
were higher with c a p 1 therapy. although the nega-
tive resource and quality-of-life impacts of these 
events are self-explanatory, they may have affected 
survival either positively or negatively. Severity of 
side effects of chemotherapy has been associated with 
higher response rates and longer survival in advanced 
colorectal cancer 19. However, until this association 
is proven prospectively in esophagogastric can-
cer, the merits of first-line therapy with other than 
fluorouracil–cisplatin should be carefully considered 
in view of the toxicity encountered.
t a b l e  iii  Clinical trial results of chemotherapy in metastatic esophagogastric cancer
Reference Regimen Site Pts Prior Median 95% 2-Year Quality t r m Adeno-
(n) chemotherapy survival C i survival of life (%) carcinoma
(months) (%) (%)
Webb et al., 1997 10 e c f Esophagogastric 111 No 8.9 n r 11 e c f >f a m t x 0.9 100
f a m t x 108 No 5.7 n r 6 1.9
ross et al., 2002 11 e c f Esophagogastric 289 No 9.4 n r 15.8 e c f >m c f 0.3 93.1
m c f 285 No 8.7 n r 14.2 0.4 93.0
Pozzo et al., 2004 14 f o l f i r i Gastric 59 5.4% 10.7 8 to 14.6 13 f o l f i r i>i r i +c 0 100
dank et al., 2005 12 f o l f i r i Esophagogastric 170 Permitted 9 8.3 to 10.2 14 Trend favouring 
f o l f i r i
0.6 100
c f 163 8.7 7.8 to 9.8 12 3
roth et al., 2005 13 d c f Gastric 41 No 10.4 8.3 to 12 n r e c f >d c f 0 100
e c f 40 No 8.3 7.2 to 13 n r 0
Van Cutsem et al., 
2006 9
d c f Gastric 221 No 9.2 8.4 to 10.6 18 d c f >c f 2.7 100
c f 224 8.6 7.2 to 9.5 9 4.5
BC Cancer agency, 
this report
Esophagogastric 85 20.00% 9.7 6.2 to 13.1 10.4 n r 1.2 100
Pts = patients; c i  = confidence interval; t r m  = treatment-related mortality; e c f  = epirubicin, cisplatin, 5-fluorouracil; f a m t x  = doxorubicin, 
5-fluorouracil, leucovorin, methotrexate; n r  = not reported; m c f  = mitomycin, cisplatin, 5-fluorouracil; f o l f i r i = 5-fluorouracil, irinotecan, 
leucovorin; i r i +c = irinotecan + cisplatin; c f  = cisplatin, 5-fluorouracil; d c f  = docetaxel, cisplatin, 5-fluorouracil.13
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5.  CONCLUSIONS
The use of nonstandard chemotherapy regimens for 
surgically incurable esophagogastric adenocarcinoma 
in British Columbia has been examined and outcomes 
have been analysed. To put their own experiences into 
perspective, individual physicians need population 
outcome analyses of the kind that this review pro-
vides. Caution is, of course, required in interpreting 
retrospective nonrandomized patient cohorts. Nev-
ertheless, nonstandard chemotherapy regimens have 
substantial toxicities that should be discussed with 
patients as part of the decision process in their use.
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